Search

Copyright of Biotechnology Bulletin is the property of Biotechnology Bulletin Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the effects of cetuximab combined with irinotecan on serum tumor markers, T lymphocyte subsets and quality of life in patients with advanced gastric cancer. Methods: 104 patients with advanced gastric cancer who were treated in Baotou Central Hospital from April 2018 to April 2020 were selected, and they were divided into control group (52 cases) and observation group (52 cases) according to different treatment schemes. The control group was treated with cetuximab, and the observation group was treated with cetuximab combined with irinotecan. The clinical efficacy, adverse reactions, serum tumor markers, quality of life, T lymphocyte subsets and prognosis of the two groups were compared. Results: The clinical effective rate of the observation group was65.38%, which was higher than 25.00% of the control group (P<0.05). The disease control rate in the observation group was 71.15%,which was higher than 34.62% in the control group (P<0.05). Compared with the control group, the levels of carbohydrate antigen 199 (CA199), carbohydrate antigen 724 (CA724) and carcinoembryonic antigen (CEA) in the observation group were lower after treatment (P<0.05). The levels of CD3+, CD4+, CD4+/CD8+ in the observation group were higher than those in the control group after treatment (P<0.05). The level of CD8+in the observation group was lower than that in the control group after treatment (P<0.05). After treatment, the scores of quality of life in the observation group were higher than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 13.46%, lower than 15.38% in the control group, but there was no significant difference (P>0.05). The1-year median survival time of the control group was 6.16 months, which was shorter than 8.34 months of the observation group (logrank x²=4.219,P=0.040). Conclusion: cetuximab combined with irinotecan in the treatment of advanced gastric cancer can effectively prevent tumor progression, improve clinical efficiency and quality of life, improve the level of T lymphocyte subsets, prolong the survival time of patients, and have good safety. [ABSTRACT FROM AUTHOR]